The pioneer in developing therapeutic filtration devices to handle infectious disease and tumor.

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay Aethlon Medical, Inc. , the pioneer in developing therapeutic filtration devices to handle infectious disease and tumor, announced today that it offers filed a provisional patent on behalf of its wholly possessed subsidiary Exosome Sciences, Inc. , associated with the advancement of an assay that may allow researchers to detect exosomes in bloodstream and other liquids caverta . Beyond the potential therapeutic great things about eliminating immunosuppressive exosomes from circulation, experts acknowledge that exosomes represent a significant diagnostic target to determine progression and prognosis of both cancers and infectious disease circumstances.

Aeterna’s AEZS-108 final Phase 2 outcomes in endometrial cancer to be presented at ESGO 2011 Aeterna Zentaris Inc. The trial was conducted by the German AGO Research study and Group centers in Bulgaria. AEZS-108, a targeted cytotoxic peptide conjugate, is definitely in Phase 1/2 applications in prostate and bladder cancers currently, and has completed Stage 2 trials in endometrial and ovarian tumor successfully.

Copyright blindserver.com 2017